A carregar...
Outcomes of Immune Thrombotic Thrombocytopenic Purpura (iTTP) With Upfront Cyclophosphamide vs. Rituximab
Background: Immune thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening disorder managed with plasma exchange (PLEX) and steroids. Addition of rituximab (RTX) to initial disease treatment has been shown to lower future relapse rates. Information as to whether upfront cyclophosphami...
Na minha lista:
| Publicado no: | Front Med (Lausanne) |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7657267/ https://ncbi.nlm.nih.gov/pubmed/33195351 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmed.2020.588526 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|